Navigation Links
NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
Date:10/2/2007

SOPHIA ANTIPOLIS, France, Oct. 2 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced the presentation of promising clinical and preclinical results from its collaboration with Ferrer Grupo International at the 21st World Congress of Dermatology, in Buenos Aires, Argentina. These included phase 1 results for NCX 1022, a prototype compound, showing the potential for improved safety and tolerability and preclinical results for a novel, high potency, nitric oxide-donating anti-inflammatory suggesting it could have enhanced anti-inflammatory activity over current dermatology products.

Ennio Ongini, Vice President of Research at NicOx, declared: "We are delighted to present these very promising results with Ferrer at this prestigious scientific meeting. These results highlight the potential of our technology in dermatology and suggest our joint program with Ferrer has the potential to provide more effective drugs to treat chronic skin disorders, which represent an increasing burden on medical services. Furthermore, the clinical data on NCX 1022 suggest that nitric oxide donation may also improve the safety margin over current treatments. We will continue to work closely with Ferrer to bring our promising drug candidate into clinical trials."

NicOx and Ferrer initiated their development program focused on high potency, nitric oxide-donating anti-inflammatory agents, for the treatment of a range of skin disorders (see NOTE), following encouraging results from a phase 1 study for NCX 1022, a lower potency prototype (see top-line results in press release of April 29, 2004). This presentation at the World Congress of Dermatology was the first time these results were presented at a scientific meeting. The results showed that the application of NCX 1022 ointment did not induce skin blanching with there being statistically significantly less skin blanching with NCX 1022 compared with three commonly used marketed products (p<0.001).

In par
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... SAN DIEGO, Feb. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... patient enrollment in its bioequivalence study of ANX-514 (docetaxel ... announce results from this study in the second quarter ... chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved ...
... to monitor health outcomes in Fresno, California LOS ALTOS, ... Foundation (GHRF) today announced that it has received a ... treatment in California,s Central Valley, a region with the ... grant will help fund data collection and analysis at ...
Cached Medicine Technology:ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 2ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 3Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley 2
(Date:7/13/2014)... in The Lancet Neurology calls for ... term neurological problems that repeated concussions can cause. ... of sports-related traumatic brain injury (TBI), and the ... amyotrophic lateral sclerosis, and other neurological disorders, say ... concerning, is that even when the symptoms of ...
(Date:7/13/2014)... 13, 2014 Carolinas Healthcare System celebrated ... the Carolinas HealthCare System - Anson located in Anson ... Anson Community Hospital in Wadesboro. , Located on U.S. ... from the previous facility. Situated on a 10-acre site, ... an emergency room drop-off, helipad, healing garden, and 15 ...
(Date:7/13/2014)... portable, microchip-based test for diagnosing type-1 diabetes could ... understand the disease, according to the device,s inventors ... Described in a paper to be published online ... test employs nanotechnology to detect type-1 diabetes outside ... two main forms of diabetes mellitus, which are ...
(Date:7/13/2014)... Victorian Hotel has recently announced that it ... bikes for its "Cycle the City" program, which encourages ... the area using a rental bicycle, available for just ... call Vancouver home, as it is a city with ... journeys through the countryside. Vancouver hotel rooms often play ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... high health-care costs it has become a burden both on ... as a respite comes a new cardio drug that negates ... ,The drug is in the African-American heart failure patients where ... Angus, M.D., M.P.H., professor of critical care medicine at the ...
... A liver transplant operation has been conducted on a six-year-old ... underwent the surgery celebrates his birthday on 19 December 2005. ... 'The kid is still in ICU but is responding well ... hope his condition will be normal soon.' , ,He ...
... Clinic say that the flagship breast cancer drug, tamoxifen might ... genetic variation. // ,This particular variant gene has the ... is vital to activate tamoxifen against breast cancer. The study ... of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an ...
... is responsible for the death of Rene Anderson, a diabetic ... was prescribed to Mrs. Anderson to ease the numbness and ... // ,The medicine is reported to have resulted disturbed ... an intoxicated and confused state. Here her condition continued to ...
... formed a new cabinet committee to plan strategies to fight ... said that though the United Kingdom //Government has taken various ... spread but the committee feels still a lot has to ... committee feels that the Government should organize the food sector ...
... easily subsided by administering sweet to children now has a ... ,They have reported that the analgesic efficacy of sweet ... sweet taste and by the child's weight status. This appears ... just because they taste good, but also because sweets make ...
Cached Medicine News:Health News:A cost effective heart failure drug hits the market! 2Health News:Sweet pain releiver! 2
... Workstations provide comprehensive neurological monitoring in ... unit to accurately access your patients ... 15 years experience, and a long ... neurological monitoring systems have a proven ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... system especially designed for surgical monitoring and ... channels and is equipped with two headboxes ... can be independently configured as either a ... Endeavor amplifiers are based on the Firewire ...
Medicine Products: